ARTICLE SUMMARY:
While the initial hype surrounding RDN has largely disappeared, Medtronic’s efforts over the past seven years may finally be about to pay off—in a big way, the company hopes. We speak with the head of its renal denervation group about MDT’s ongoing clinical programs and upcoming US regulatory submission, and its path to a potentially enormous market.
More than a decade after Medtronic plc entered the renal denervation (RDN) market with the purchase of Ardian, and seven years after the high-profile failure of the first sham-controlled RDN trial, the company finally has US approval within its sights. It’s been a long and bumpy road, but Medtronic believes the payoff to come over the next five to 10 years will be well worth the effort.
